News | November 16, 2025
Kilitch Drugs H! FY26 PAT up 18% YoY to Rs. 10.30 Cr
Total income for the period stood at Rs. 7101.28 crore
Total income for the period stood at Rs. 7101.28 crore
The new formulation features what Abbott calls a “triple care system,” anchored by a blend of nutrients aimed at supporting blood sugar control and metabolic health
This collaboration turns kitting into a strategic advantage for sponsors and sites
Diversifying its portfolio to include late-phase antiviral agent
Sepsis is a life-threatening reaction to infection that overwhelms the body’s defenses
The FDA is initiating removal of the boxed warnings following a comprehensive review of the scientific literature
Novartis is the only pharmaceutical company with a dedicated commercial RLT portfolio
False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample
Fenebrutinib targets cells in the immune system known as B cells and microglia
Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes
Subscribe To Our Newsletter & Stay Updated
